Genetics of fibrosing lung diseases

European Respiratory Journal

Volumn 25, Issue 5, 2005, Pages 915-927

  Grutters, J C ^a   du Bois, R M ^b  

^a ST ANTONIUS HOSPITAL   (Netherlands)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Familial; Genetics; Interstitial lung disease; Pulmonary fibrosis

Indexed keywords

AUTOANTIBODY; CENTROMERE ANTIBODY; COMPLEMENT RECEPTOR; DNA TOPOISOMERASE; HLA DP ANTIGEN; HLA DR ANTIGEN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6; SURFACTANT PROTEIN C; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR 2;

ALLELE; ANGIOGENESIS; APOPTOSIS; CELL MIGRATION; CELL PROLIFERATION; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; EXTRACELLULAR MATRIX; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENOTYPE; HOMEOSTASIS; HUMAN; INCIDENCE; LUNG FIBROBLAST; LUNG FIBROSIS; LUNG TRANSPLANTATION; MAJOR HISTOCOMPATIBILITY COMPLEX; OCULAR ALBINISM; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SYSTEMIC SCLEROSIS; TH1 CELL; TH2 CELL;

HERMANSKI-PUDLAK SYNDROME; HUMANS; MUTATION; POLYMORPHISM, GENETIC; PULMONARY FIBROSIS; PULMONARY SURFACTANT-ASSOCIATED PROTEIN C; SCLERODERMA, SYSTEMIC;

EID: 18744374226     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.05.00133404     Document Type: Review

References (94)

1. Cushley MJ, Davison AG, du Bois RM, et al. The diagnosis, assessment and treatment of diffuse parenchymal lung disease in adults. British Thoracic Society recommendations. Thorax 1999; 54: Suppl. 1, S1-S30.
2. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med 2002; 165: 277-304.
3. Steele MP, Speer MC, Loyd JE, et al. Familial pulmonary fibrosis (FPF) in the United States: clinical characteristics and patterns of inheritance. Am J Respir Crit Care Med 2004; 169: A550.
4. Coultas DB, Zumwalt RE, Black WC, Sobonya RE. The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med 1994; 150: 967-972.
5. Marshall RP, Puddicombe A, Cookson WO, Laurent GJ. Adult familial cryptogenic fibrosing alveolitis in the United Kingdom. Thorax 2000; 55: 143-146.
6. Loyd JE. Pulmonary fibrosis in families. Am J Respir Cell Mol Biol 2003; 29: Suppl. 3, S47-S50.
7. Hodgson U, Laitinen T, Tukiainen P. Nationwide prevalence of sporadic and familial idiopathic pulmonary fibrosis: evidence of founder effect among multiplex families in Finland. Thorax 2002; 57: 338-342.
8. Thomas AQ, Lane K, Phillips J III, et al. Heterozygosity for a surfactant protein C gene mutation associated with usual interstitial pneumonitis and cellular nonspecific interstitial pneumonitis in one kindred. Am J Respir Crit Care Med 2002; 165: 1322-1328.
9. Bitterman PB, Rennard SI, Keogh BA, Wewers MD, Adelberg S, Crystal RG. Familial idiopathic pulmonary fibrosis. Evidence of lung inflammation in unaffected family members. N Engl J Med 1986; 314: 1343-1347.
10. Musk AW, Zilko PJ, Manners P, Kay PH, Kamboh MI. Genetic studies in familial fibrosing alveolitis. Possible linkage with immunoglobulin allotypes (Gm). Chest 1986; 89: 206-210.
11. Nogee LM, Dunbar AE III, Wert SE, Askin F, Hamvas A, Whitsett JA. A mutation in the surfactant protein C gene associated with familial interstitial lung disease. N Engl J Med 2001; 344: 573-579.
12. Wang WJ, Mulugeta S, Russo SJ, Beers MF. Deletion of exon 4 from human surfactant protein C results in aggresome formation and generation of a dominant negative. J Cell Sci 2003; 116: 683-692.
13. Fisher JH, Emrie PA, Drabkin HA, et al. The gene encoding the hydrophobic surfactant protein SP-C is located on 8p and identifies an EcoRI RFLP. Am J Hum Genet 1988; 43: 436-441.
14. Glasser SW, Korfhagen TR, Perme CM, Pilot-Matias TJ, Kister SE, Whitsett JA. Two SP-C genes encoding human pulmonary surfactant proteolipid. J Biol Chem 1988; 263: 10326-10331.
15. Brasch F, Griese M, Tredano M, et al. Interstitial lung disease in a baby with a de novo mutation in the SFTPC gene. Eur Respir J 2004; 24: 30-39.
16. Tredano M, Griese M, Brasch F, et al. Mutation of SFTPC in infantile pulmonary alveolar proteinosis with or without fibrosing lung disease. Am J Med Genet 2004; 126A: 18-26.
17. Riva A, Kohane IS. SNPper: retrieval and analysis of human SNPs. Bioinformatics 2002; 18: 1681-1685. Version 118. http://snpper.chip.org/bio/show-sequence/?TYPE=U&GENE=18686. Date last accessed: October 6 2004.
18. Whitsett JA. Genetic basis of familial interstitial lung disease: misfolding or function of surfactant protein C? Am J Respir Crit Care Med 2002; 165: 1201-1202.
19. Baatz JE, Smyth KL, Whitsett JA, Baxter C, Absolom DR. Structure and functions of a dimeric form of surfactant protein SP-C: a Fourier transform infrared and surfactometry study. Chem Phys Lipids 1992; 63: 91-104.
20. Amin RS, Wert SE, Baughman RP, et al. Surfactant protein deficiency in familial interstitial lung disease. J Pediatr 2001; 139: 85-92.
21. Anderson PD, Huizing M, Claassen DA, White J, Gahl WA. Hermansky-Pudlak syndrome type 4 (HPS-4): clinical and molecular characteristics. Hum Genet 2003; 113: 10-17.
22. Dell'Angelica EC, Ooi CE, Bonifacino JS. β3A-adaptin, a subunit of the adaptor-like complex AP-3. J Biol Chem 1997; 272: 15078-15084.
23. Huizing M, Sarangarajan R, Strovel E, Zhao Y, Gahl WA, Boissy RE. AP-3 mediates tyrosinase but not TRP-1 trafficking in human melanocytes. Mol Biol Cell 2001; 12:2075-2085.
24. Nakatani Y, Nakamura N, Sano J, et al. Interstitial pneumonia in Hermansky-Pudlak syndrome: significance of florid foamy swelling/degeneration (giant lamellar body degeneration) of type-2 pneumocytes. Virchows Arch 2000; 437: 304-313.
25. Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001; 134: 136-151.
26. Selman M, Pardo A. The epithelial/fibroblastic pathway in the pathogenesis of idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 2003; 29: Suppl. 3, S93-S97.
27. Colhoun HM, McKeigue PM, Davey SG. Problems of reporting genetic associations with complex outcomes. Lancet 2003; 361: 865-872.
28. du Bois RM. The genetic predisposition to interstitial lung disease: functional relevance. Chest 2002; 121: Suppl. 3, 14S-20S.
29. Hutyrova B, Pantelidis P, Drabek J, et al. Interleukin-1 gene cluster polymorphisms in sarcoidosis and idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2002; 165: 148-151.
30. Whyte M, Hubbard R, Meliconi R, et al. Increased risk of fibrosing alveolitis associated with interleukin-1 receptor antagonist and tumor necrosis factor-α gene polymorphisms. Am J Respir Crit Care Med 2000; 162: 755-758.
31. Riha RL, Yang IA, Rabnott GC, Tunnicliffe AM, Fong KM, Zimmerman PV. Cytokine gene polymorphisms in idiopathic pulmonary fibrosis. Intern Med J 2004; 34: 126-129.
32. Pantelidis P, Fanning GC, Wells AU, Welsh KI, du Bois RM. Analysis of tumor necrosis factor-α, lymphotoxin-α, tumor necrosis factor receptor II, and interleukin-6 polymorphisms in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2001; 163: 1432-1436.
33. Whittington HA, Freeburn RW, Godinho SI, Egan J, Haider Y, Millar AB. Analysis of an IL-10 polymorphism in idiopathic pulmonary fibrosis. Genes Immun 2003; 4: 258-264.
34. Renzoni E, Lympany P, Sestini P, et al. Distribution of novel polymorphisms of the interleukin-8 and CXC receptor 1 and 2 genes in systemic sclerosis and cryptogenic fibrosing alveolitis. Arthritis Rheum 2000; 43: 1633-1640.
35. Latsi P, Pantelidis P, Vassilakis D, Sato H, Welsh KI, du Bois RM. Analysis of IL-12 p40 subunit gene and IFN-γ G5644A polymorphisms in idiopathic pulmonary fibrosis. Respir Res 2003; 4: 6. http://respiratory-research.com/content/4/1/6.
36. Zorzetto M, Bombieri C, Ferrarotti I, et al. Complement receptor 1 gene polymorphisms in sarcoidosis. Am J Respir Cell Mol Biol 2002; 27: 17-23.
37. Selman M, Lin HM, Montano M, et al. Surfactant protein A and B genetic variants predispose to idiopathic pulmonary fibrosis. Hum Genet 2003; 113: 542-550.
38. Kim KK, Flaherty KR, Long Q, et al. A plasminogen activator inhibitor-1 promoter polymorphism and idiopathic interstitial pneumonia. Mol Med 2003; 9: 52-56.
39. Xaubet A, Marin-Arguedas A, Lario S, et al. Transforming growth factor-β1 gene polymorphisms are associated with disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003; 168: 431-435.
40. Morrison CD, Papp AC, Hejmanowski AQ, Addis VM, Prior TW. Increased D allele frequency of the angiotensin-converting enzyme gene in pulmonary fibrosis. Hum Pathol 2001; 32: 521-528.
41. Pan LH, Ohtani H, Yamauchi K, Nagura H. Co-expression of TNF alpha and IL-1 beta in human acute pulmonary fibrotic diseases: an immunohistochemical analysis. Pathol Int 1996; 46: 91-99.
42. Nash JR, McLaughlin PJ, Butcher D, Corrin B. Expression of tumour necrosis factor-α in cryptogenic fibrosing alveolitis. Histopathology 1993; 22: 343-347.
43. Piguet PF, Ribaux C, Karpuz V, Grau GE, Kapanci Y. Expression and localization of tumor necrosis factor-α and its mRNA in idiopathic pulmonary fibrosis. Am J Pathol 1993; 143: 651-655.
44. Eskdale J, Gallagher G, Verweij CL, Keijsers V, Westendorp RG, Huizinga TW. Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proc Natl Acad Sci U S A 1998; 95: 9465-9470.
45. Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 1997; 24: 1-8.
46. Sime PJ, O'Reilly KM. Fibrosis of the lung and other tissues: new concepts in pathogenesis and treatment. Clin Immunol 2001; 99: 308-319.
47. Ando M, Miyazaki E, Fukami T, Kumamoto T, Tsuda T. Interleukin-4-producing cells in idiopathic pulmonary fibrosis: an immunohistochemical study. Respirology 1999; 4: 383-391.
48. Wallace WA, Ramage EA, Lamb D, Howie SE. A type 2 (Th2-like) pattern of immune response predominates in the pulmonary interstitium of patients with cryptogenic fibrosing alveolitis (CFA). Clin Exp Immunol 1995; 101: 436-441.
49. Prior C, Haslam PL. In vivo levels and in vitro production of interferon-gamma in fibrosing interstitial lung diseases. Clin Exp Immunol 1992; 88: 280-287.
50. Seegers D, Zwiers A, Strober W, Pena AS, Bouma G. A TaqI polymorphism in the 3′UTR of the IL-12 p40 gene correlates with increased IL-12 secretion. Genes Immun 2002; 3: 419-423.
51. Pantelidis P, Veeraraghavan S, du Bois RM. Surfactant gene polymorphisms and interstitial lung diseases. Respir Res 2002; 3: 14. http://respiratory-research.com/content/3/1/14.
52. Guo X, Lin HM, Lin Z, et al. Surfactant protein gene A, B, and D marker alleles in chronic obstructive pulmonary disease of a Mexican population. Eur Respir J 2001; 18: 482-490.
53. Lawson WE, Grant SW, Ambrosini V, et al. Genetic mutations in surfactant protein C are a rare cause of sporadic cases of IPF. Thorax 2004; 59: 977-980.
54. Cantin AM, Hubbard RC, Crystal RG. Glutathione deficiency in the epithelial lining fluid of the lower respiratory tract in idiopathic pulmonary fibrosis. Am Rev Respir Dis 1989; 139: 370-372.
55. Crystal RG. Oxidants and respiratory tract epithelial injury: pathogenesis and strategies for therapeutic intervention. Am J Med 1991; 91: Suppl. 3C, 39S-44S.
56. Katzenstein AL. Pathogenesis of "fibrosis" in interstitial pneumonia: an electron microscopic study. Hum Pathol 1985; 16: 1015-1024.
57. Kotani I, Sato A, Hayakawa H, Urano T, Takada Y, Takada A. Increased procoagulant and antifibrinolytic activities in the lungs with idiopathic pulmonary fibrosis. Thromb Res 1995; 77: 493-504.
58. Imokawa S, Sato A, Hayakawa H, Kotani M, Urano T, Takada A. Tissue factor expression and fibrin deposition in the lungs of patients with idiopathic pulmonary fibrosis and systemic sclerosis. Am J Respir Crit Care Med 1997; 156: 631-636.
59. Fujii M, Hayakawa H, Urano T, et al. Relevance of tissue factor and tissue factor pathway inhibitor for hypercoagulable state in the lungs of patients with idiopathic pulmonary fibrosis. Thromb Res 2000; 99: 111-117.
60. Noble PW. Idiopathic pulmonary fibrosis. New insights into classification and pathogenesis usher in a new era therapeutic approaches. Am J Respir Cell Mol Biol 2003; 29, Suppl. 3, S27-S31.
61. Sime PJ, Xing Z, Graham FL, Csaky KG, Gauldie J. Adenovector-mediated gene transfer of active transforming growth factor-β1 induces prolonged severe fibrosis in rat lung. J Clin Invest 1997; 100: 768-776.
62. Kolb M, Bonniaud P, Ask K, et al. TGFβ3 has differential effects in the lung dependent on the underlying pathogenetic condition. Eur Respir J 2003; 24: Suppl. 48, 481s.
63. Grainger DJ, Heathcote K, Chiano M, et al. Genetic control of the circulating concentration of transforming growth factor type β1. Hum Mol Genet 1999; 8: 93-97.
64. Otsuka M, Takahashi H, Shiratori M, Chiba H, Abe S. Reduction of bleomycin induced lung fibrosis by candesartan cilexetil, an angiotensin II type 1 receptor antagonist. Thorax 2004; 59: 31-38.
65. Nguyen L, Ward WF, Ts'ao CH, Molteni A. Captopril inhibits proliferation of human lung fibroblasts in culture: a potential antifibrotic mechanism. Proc Soc Exp Biol Med 1994; 205: 80-84.
66. Nadrous HF, Ryu JH, Douglas WW, Decker PA, Olson EJ. Impact of angiotensin-converting enzyme inhibitors and statins on survival in idiopathic pulmonary fibrosis. Chest 2004; 126: 438-446.
67. Cambien F, Alhenc-Gelas F, Herbeth B, et al. Familial resemblance of plasma angiotensin-converting enzyme level: the Nancy Study. Am J Hum Genet 1988; 43: 774-780.
68. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990; 86: 1343-1346.
69. Fatini C, Gensini F, Sticchi E, et al. High prevalence of polymorphisms of angiotensin-converting enzyme (I/D) and endothelial nitric oxide synthase (Glu298Asp) in patients with systemic sclerosis. Am J Med 2002; 112: 540-544.
70. Zuo F, Kaminski N, Eugui E, et al. Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans. Proc Natl Acad Sci U S A 2002; 99: 6292-6297.
71. Kaminski N. Microarray analysis of idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 2003; 29: Suppl. 3, S32-S36.
72. Winkler MK, Fowlkes JL. Metalloproteinase and growth factor interactions: do they play a role in pulmonary fibrosis? Am J Physiol Lung Cell Mol Physiol 2002; 283: L1-L11.
73. Ramos C, Montano M, Garcia-Alvarez J, et al. Fibroblasts from idiopathic pulmonary fibrosis and normal lungs differ in growth rate, apoptosis, and tissue inhibitor of metalloproteinases expression. Am J Respir Cell Mol Biol 2001; 24: 591-598.
74. Phan SH. Fibroblast phenotypes in pulmonary fibrosis. Am J Respir Cell Mol Biol 2003; 29: Suppl. 3, S87-S92.
75. du Bois RM. Sarcoidosis: do our genes really matter? Am J Respir Crit Care Med 2001; 164: 725-726.
76. Hojo S, Fujita J, Yamadori I, et al. Heterogeneous point mutations of the p53 gene in pulmonary fibrosis. Eur Respir J 1998; 12: 1404-1408.
77. Keane MP, Arenberg DA, Lynch JP III, et al. The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis. J Immunol 1997; 159: 1437-1443.
78. Renzoni EA. Neovascularization in idiopathic pulmonary fibrosis: too much or too little? Am J Respir Crit Care Med 2004; 169: 1179-1180.
79. Ebina M, Shimizukawa M, Shibata N, et al. Heterogeneous increase in CD34-positive alveolar capillaries in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2004; 169: 1203-1208.
80. Cosgrove GP, Brown KK, Schiemann WP, et al. Pigment epithelium-derived factor in idiopathic pulmonary fibrosis: a role in aberrant angiogenesis. Am J Respir Crit Care Med 2004; 170: 242-251.
81. Bouros D, Wells AU, Nicholson AG, et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002; 165: 1581-1586.
82. Jimenez SA, Derk CT. Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis. Ann Intern Med 2004; 140: 37-50.
83. Briggs DC, Vaughan RW, Welsh KI, Myers A, Dubois RM, Black CM. Immunogenetic prediction of pulmonary fibrosis in systemic sclerosis. Lancet 1991; 338: 661-662.
84. Gilchrist FC, Bunn C, Foley PJ, et al. Class II HLA associations with autoantibodies in scleroderma: a highly significant role for HLA-DP. Genes Immun 2001; 2: 76-81.
85. Vlachoyiannopoulos PG, Dafni UG, Pakas I, Spyropoulou-Vlachou M, Stavropoulos-Giokas C, Moutsopoulos HM. Systemic scleroderma in Greece: low mortality and strong linkage with HLA-DRB1*1104 allele. Ann Rheum Dis 2000; 59: 359-367.
86. Johnson RW, Tew MB, Arnett FC. The genetics of systemic sclerosis. Curr Rheumatol Rep 2002; 4: 99-107.
87. Mayes MD. Scleroderma epidemiology. Rheum Dis Clin North Am 2003; 29: 239-254.
88. Sato H, Lagan AL, Alexopoulou C, et al. The TNF-863A allele strongly associates with anticentromere antibody positivity in scleroderma. Arthritis Rheum 2004; 50: 558-564.
89. Sugiura Y, Banno S, Matsumoto Y, et al. Transforming growth factor β1 gene polymorphism in patients with systemic sclerosis. J Rheumatol 2003; 30: 1520-1523.
90. Crilly A, Hamilton J, Clark CJ, Jardine A, Madhok R. Analysis of transforming growth factor β1 gene polymorphisms in patients with systemic sclerosis. Ann Rheum Dis 2002; 61: 678-681.
91. Avila JJ, Lympany PA, Pantelidis P, Welsh KI, Black CM, du Bois RM. Fibronectin gene polymorphisms associated with fibrosing alveolitis in systemic sclerosis. Am J Respir Cell Mol Biol 1999; 20: 106-112.
92. Zhou X, Tan FK, Reveille JD, et al. Association of novel polymorphisms with the expression of SPARC in normal fibroblasts and with susceptibility to scleroderma. Arthritis Rheum 2002; 46: 2990-2999.
93. Tan FK, Wang N, Kuwana M, et al. Association of fibrillin 1 single-nucleotide polymorphism haplotypes with systemic sclerosis in Choctaw and Japanese populations. Arthritis Rheum 2001; 44: 893-901.
94. Udalova IA, Richardson A, Denys A, et al. Functional consequences of a polymorphism affecting NF-κB p50-p50 binding to the TNF promoter region. Mol Cell Biol 2000; 20: 9113-9119.